Study of Vitamin D Supplementation to Male HIV Sero-positive Patients
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The investigators want to investigate if HIV sero-positive males benefit from vitamin D
supplementation. The study runs in 16 weeks and the participants are treated with one of
three placebo controlled regimes (tablets):
1. Calcium
2. Calcium and 25-hydroxy-vitamin D
3. Calcium and 25-hydroxy-vitamin D and 1,25-dihydroxyvitamin D
The endpoints are:
- Serum vitamin D
- Parathyroid hormone
- ionized calcium
- T-lymphocyte fractions (naïve, mature, Tregs)
- Osteocalcin (bone metabolism)
Phase:
N/A
Details
Lead Sponsor:
Hvidovre University Hospital
Treatments:
Calcitriol Calcium Calcium, Dietary Ergocalciferols Vitamin D Vitamins